A new medicine for treating schizophrenia—one that appears to help reduce both positive and negative symptoms of the illness—has passed a first hurdle in phase 3 clinical testing. Phase 3 is often…
Read More
A team led by BBRF grantees has proposed a markedly new way of understanding the role of dopamine in the brain in processes involved in learning and memory. The revised view of the neurotransmitter…
Read More
A team of researchers has reported progress in testing a new approach involving the dopamine system that they hope may help reduce symptoms of post-traumatic stress disorder (PTSD).
Read More
In the continuing effort to develop new medicines to treat schizophrenia, a team led by BBRF Scientific Council member Jeffrey Lieberman, M.D., and including nine other Council Members, BBRF grantees…
Read More
By inhibiting a previously untargeted nerve-cell receptor in the brain, researchers have discovered a new class of compounds that may be useful in the treatment of schizophrenia. In animal models of…
Read More
